Infinimmune raises $75M
Infinimmune announced a Series A round of $75M on 12 August 2026. The company operates in HealthTech and is based in United States. It was founded by Wyatt McDonnell, Co-Founder & CEO.
Founder
Wyatt McDonnell
Co-Founder & CEO, Infinimmune
Outreach angles
- -Co-founded and leads Infinimmune as CEO, pursuing a human-derived approach to antibody drug discovery.
- -Struck a research collaboration with Immunome and secured backing from Regeneron Ventures for Infinimmune's antibody platform.
- -Closed a $75 million Series A to advance Infinimmune's pipeline of human-derived antibodies for atopic dermatitis and inflammatory disease.
Signals
Series AHealthcareDeep TechRegulated IndustryB2B
Round details
Company: Infinimmune
Domain: infinimmune.com
Amount: $75M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 12 August 2026
Other HealthTech raises
Recently funded in United States